Compare HWBK & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | TNXP |
|---|---|---|
| Founded | 1865 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.2M | 198.6M |
| IPO Year | 1996 | 2008 |
| Metric | HWBK | TNXP |
|---|---|---|
| Price | $33.25 | $13.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.4K | ★ 364.8K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | 31.42 | ★ 91.75 |
| EPS | ★ 3.43 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $10.01 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $27.07 | $11.60 |
| 52 Week High | $36.25 | $69.65 |
| Indicator | HWBK | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 51.84 |
| Support Level | $32.90 | $13.32 |
| Resistance Level | $34.10 | $14.52 |
| Average True Range (ATR) | 0.90 | 0.74 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 20.75 | 65.08 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.